An observational study in Breast Cancer, sponsored by Samsung Medical Center. Active, not recruiting at 1 site in South Korea. Open to female participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Samsung Medical Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Breast Neoplasms by Samsung Medical Center — 13 open to participants now, 16 under way, 1 of them phase 3. Breast Neoplasms · Samsung Medical Center.
Among the 47 studies in Breast Neoplasms by Samsung Medical Center, this one is the 7th largest by planned enrollment of the 19 observational ones that give a count, is one of 2 that started in 2021, is one of 19 observational ones, reaches primary completion later than 13 of the 15 other live ones, and was the 45th registered.
14,848 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.
Browse Breast Neoplasms studies →13 of the 47 studies in Breast Neoplasms by Samsung Medical Center are open now, in 1 country. Recruiting first, the newest first:
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+ · Women only
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
Samsung Medical Center · Sites in Korea, Republic of
Ages 18–65 · Women only
Samsung Medical Center · Sites in Korea, Republic of
Women only · Healthy volunteers
Samsung Medical Center · Sites in Korea, Republic of
Ages 18–100 · Women only
By country, each count listing its studies:
Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 19 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 3 · Phase 4 1
First in 2007; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 184 across 3,237 observational studies indexed under Breast Neoplasms.
Median enrollment 147 across the 27 interventional studies, 400 across the 19 observational. Of the 12 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Samsung Medical Center is the lead sponsor of 1,013 studies on the registry; 153 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 47 studies in Breast Neoplasms by Samsung Medical Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Investigators conducted genomic sequencing including genome sequencing/exome sequencing/RNASeq and spatial transcriptomics of BC having dismal prognosis
Patient diagnosed as Breast cancer
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
No intervention would be needed
Disease free survival
Time between BC diagnosis and any recurrence
Time frame: Through study completion, an average 3 years
Disease free survival depending on genomic characteristics
Duration between BC diagnosis and any disease recurrence detected
Time frame: Through study completion, an average 3 years
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jan 2021 (actual). Primary completion is estimated for Dec 2030, 119 months after the start.
Of 1,192 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 138. This study's planned 119 months is above that.
Counting every sponsor, half of 1,381 studies reached it within 55 months; a quarter within 25 and three quarters within 126.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.